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Abstract
Biomarkers of sepsis could allow early identification of high-risk
patients, in whom aggressive interventions can be life-saving.
Among those interventions are the immunomodulatory therapies,
which will hopefully become increasingly available to clinicians.
However, optimal use of such interventions will probably be patient
specific and based on longitudinal profiles of such biomarkers.
Modeling techniques that allow proper interpretation and
classification of these longitudinal profiles, as they relate to patient
characteristics, disease progression, and therapeutic interventions,
will prove essential to the development of such individualized
interventions. Once validated, these models may also prove useful
in the rational design of future clinical trials and in the interpretation
of their results. However, only a minority of mathematicians and
statisticians are familiar with these newer techniques, which have
undergone remarkable development during the past two decades.
Interestingly, critical illness has the potential to become a key
testing ground and field of application for these emerging modeling
techniques, given the increasing availability of point-of-care testing
and the need for titrated interventions in this patient population.
Critical care physicians titrate care of individual patients
based on presumed diagnosis derived from available data
and anticipated progression of disease. The problem of
sepsis in the intensive care unit has proven particularly vexing
because both components of the decision-making process
are insufficiently characterized. The problem is compounded
by the fact that interventions in severely septic patients are
time critical, the data are complex, and there is at least
theoretical potential for harming patients with immuno-
modulation of the host response to an infectious challenge.
In the previous issue of Critical Care, Kyr and coworkers [1]
introduce a sophisticated statistical technique for modeling
longitudinal data. Given baseline values of serum C-reactive
protein (CRP) and patient characteristics, the models
presented have the ability to predict future levels of CRP,
across diagnostic categories and patient characteristics. The
authors recognize their work to be exploratory, and limited by
the small size of the cohort, lack of a validation group, and
inability to include predictors in the models that could
significantly enhance the applicability of the predictions to
more refined subgroups or individual patients. However, the
work is relevant to critical illness.
The critical care community’s best effort to address sepsis is
crystallized in the recommendations of the Surviving Sepsis
campaign [2]. Despite conflicting reports on the efficacy of
immunomodulation in sepsis, there is a prevailing view that
future, decisive improvement in outcomes will result from
targeted, biomarker-guided immunomodulation [3,4]. However,
how the targeting should be achieved and how biomarker
profiles should be interpreted remain open fields of inquiry. In
this regard, the development of data-driven models that
‘explain’ the dynamics of markers of septic physiology may
prove useful.
There are, however, two caveats. First, in view of observed
variability between patients, how confident can one be when
ascribing an individual patient to a specific disease subgroup,
and how soon during the course of disease can this be
accomplished? Such knowledge could help in selecting a
therapeutic strategy that is most appropriate for the particular
disease subgroup. The second caveat pertains to the
assumption that disease modification is reflected in a longi-
tudinal biomarker profile and, vice versa, that modification to
this time course reflects disease modification. Whether this
assumption is valid will in all likelihood depend on the
mechanistic role played by the biomarker in the disease
process. A corollary of this observation is that, in the absence
of actual data describing the evolution of biomarker data in
the presence and absence of treatment with a given thera-
peutic agent, it is unlikely that such models - in isolation - can
direct titrated care. This would best be accomplished by a
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type of mechanistic model that ‘understands’ the drivers of
disease progression.
These considerations may herald a more immediate useful-
ness of statistical modeling of longitudinal data in acute
illness. We anticipate that knowledge-driven mechanistic
disease models will be most useful in describing the
molecular and physiologic manifestations of acute illnesses
such as sepsis [5-8] and will be necessary to augment the
rational design of upcoming clinical trials of immuno-
modulators in sepsis [9,10]. However, such models are
difficult to design and to calibrate from existing data.
Furthermore, the methods used to adapt mechanistic models
to describe individualized disease progression are still under
intense development [11]. There exists a definite comple-
mentarity between the class of models presented by Kyr and
coworkers [1] and such mechanistic models. Statistical
models that reliably segregate physiologic classes of severity
[12] and quantify patient heterogeneity could assist in
designing and calibrating relevant mechanistic models.
Indeed, Kyr and coworkers [1] report that physiologic
abnormalities take longer to resolve in patients with the most
severe forms of sepsis, and that trauma and surgery are
associated with more modest increases in CRP. These
findings are clearly related to underlying physiologic
mechanisms and represent predictions that must be made
quantitatively by mechanistic models of sepsis [13].
The past few years have witnessed an increasing number of
reports that employ sophisticated modeling techniques in the
description and prognostication of acute illness, and in the
rational design and interpretation of bench-top experiments.
Access to these techniques will require the input of a greater
number of quantitative scientists with an enhanced range of
expertise. Similarly, this increased level of sophistication must
not be a disincentive to editors of clinical journals to publish
such papers. Rather, the current pool of reviewers of most
clinical journals must be extended to quantitative scientists,
as most senior editors have realized. The large scientific
societies that represent critical care practitioners must play a
leadership role by offering a forum for the quantitative and
clinical scientists who are currently promoting these new
modeling approaches, and who are much under-represented
at international meetings. Smaller societies, such as the
Society for Complexity in Acute Illness are pioneering in this
field, offering a tantalizing forum for applications of new,
sophisticated modeling methods in acute care [14] and a
platform for computer scientists, engineers, statisticians,
mathematicians, biologic scientists, and clinicians to share
challenges and ideas [13]. Clinicians should not only be part
of this wave, but they must lead in clearly communicating a
research agenda that is of transitional relevance.
To conclude, sophisticated new statistical techniques of
class identification and trajectory analysis promise to improve
diagnosis, prognostication, and titration in critical care. These
techniques are complementary to a growing array of
mechanistic disease models, and will prove essential to the
development of rational drug design and targeted care in
critical illness.
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